BUREN has advised Alimera Sciences, Inc., a pharmaceutical company listed on the Nasdaq that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, on the refinancing of its existing debt with Solar Capital Ltd. Alimera Sciences Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases.
Solar Capital Ltd. is a closed-end investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. A specialty finance company with expertise in several niche markets, Solar Capital primarily invests in leveraged, U.S. middle market companies in the form of senior secured cash flow and asset-based investments. Solar Capital’s life science lending business provides financing solutions for bio-pharma, medical device, healthcare IT and healthcare services companies, both venture-backed private and public, and from pre-revenue clinical to early commercial stage.
The beginning of a new year is a great moment for an overview of recent developments in the law. I
Peter van Dijk and IJsbrand Uljée had the opportunity to write the Dutch chapter in the ICLG "International Comparative Legal Guide to: Corporate Tax 2020".
On 28 November 2019, the Dutch State Secretary of Finance published a (draft) decree including changes of